Ingelheim: Boehringer Ingelheim and CDR-Life, Inc. have announced a new global licensing agreement to develop CDR-Life’s unique antibody based molecule CDR111 for autoimmune diseases.

CDR111 is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.

Dysregulated B cells play a central role in driving many autoimmune and inflammatory conditions such as lupus, multiple sclerosis and certain forms of arthritis. Therefore, an approach that can deeply deplete these cells could have broad and far-reaching potential across multiple indications.

The agreement builds on the companies’ successful collaboration on an investigational antibody fragment. Boehringer has developed this molecule with tech

See Full Page